Clinical trial
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
NCT00438789 · Alexion Pharmaceuticals, Inc., Industry · Approved for marketing
Key facts
| NCT number | NCT00438789 |
|---|---|
| Title | The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol |
| Acronym | EMBRACE |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Hemoglobinuria, Paroxysmal |
| Intervention type | Drug |
| Interventions | eculizumab |
| First posted | Feb 22, 2007 |
| Last update posted | May 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: